DE60142861D1 - Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine - Google Patents

Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine

Info

Publication number
DE60142861D1
DE60142861D1 DE60142861T DE60142861T DE60142861D1 DE 60142861 D1 DE60142861 D1 DE 60142861D1 DE 60142861 T DE60142861 T DE 60142861T DE 60142861 T DE60142861 T DE 60142861T DE 60142861 D1 DE60142861 D1 DE 60142861D1
Authority
DE
Germany
Prior art keywords
molecules
acute
tif
inhibiting
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142861T
Other languages
German (de)
English (en)
Inventor
Laure Dumoutier
Jean-Christophe Renauld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of DE60142861D1 publication Critical patent/DE60142861D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
DE60142861T 2000-07-27 2001-06-27 Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine Expired - Lifetime DE60142861D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62661700A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
DE60142861D1 true DE60142861D1 (de) 2010-09-30

Family

ID=24511131

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60142861T Expired - Lifetime DE60142861D1 (de) 2000-07-27 2001-06-27 Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
DE60129137T Expired - Lifetime DE60129137D1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60129137T Expired - Lifetime DE60129137D1 (de) 2000-07-27 2001-06-27 Modulierung durch il-tif/interleukin-21

Country Status (9)

Country Link
EP (2) EP1806404B1 (enExample)
JP (1) JP4113773B2 (enExample)
CN (3) CN100497628C (enExample)
AT (2) ATE478148T1 (enExample)
AU (1) AU7303301A (enExample)
CA (1) CA2416820A1 (enExample)
DE (2) DE60142861D1 (enExample)
ES (1) ES2349312T3 (enExample)
WO (1) WO2002010393A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307161B1 (en) 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20030012788A1 (en) 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
ES2277947T3 (es) * 2000-10-13 2007-08-01 Eli Lilly And Company Procedimientos de uso de un polipeptido afin a il-17 humana para tratar enfermedades.
US7638604B2 (en) 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2003083062A2 (en) 2002-03-22 2003-10-09 Zymogenetics, Inc. Anti-il-tif antibodies and methods of using in inflammation
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
CA2497661A1 (en) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions and methods for the diagnosis of immune related diseases using pro71061
US20060177421A1 (en) * 2002-10-11 2006-08-10 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
EP1553970A1 (en) * 2002-10-11 2005-07-20 Novo Nordisk A/S Treatment of allergic conditions by use of il 21
ATE490275T1 (de) * 2003-06-23 2010-12-15 Genetics Inst Llc Antikörper gegen interleukin-22 und verwendungen dafür
EP3006466B1 (en) 2005-12-02 2018-08-01 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
IT1404858B1 (it) 2011-02-21 2013-12-09 Milano Politecnico Supporto anti-sismico.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
DE19848683B4 (de) 1998-10-22 2004-05-06 Basf Ag Verbundschichtplatte
JP3769189B2 (ja) * 1998-10-26 2006-04-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｔ細胞誘導性因子（ｔｉｆ）をコードする単離された核酸分子、コードされたタンパク質およびその使用
EP1177312B1 (en) * 1999-04-28 2007-10-31 Genetics Institute, LLC Human gil-19/ae289 proteins and polynucleotides encoding same
WO2000073457A1 (en) * 1999-05-27 2000-12-07 Schering-Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
CA2393369A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor

Also Published As

Publication number Publication date
JP2004504842A (ja) 2004-02-19
WO2002010393A2 (en) 2002-02-07
CA2416820A1 (en) 2002-02-07
WO2002010393A3 (en) 2003-01-30
CN100448994C (zh) 2009-01-07
EP1305419B1 (en) 2007-06-27
CN101423551A (zh) 2009-05-06
JP4113773B2 (ja) 2008-07-09
CN100497628C (zh) 2009-06-10
EP1305419A2 (en) 2003-05-02
CN1443241A (zh) 2003-09-17
ATE365801T1 (de) 2007-07-15
ATE478148T1 (de) 2010-09-15
CN1796558A (zh) 2006-07-05
EP1806404A1 (en) 2007-07-11
AU7303301A (en) 2002-02-13
ES2349312T3 (es) 2010-12-29
DE60129137D1 (de) 2007-08-09
EP1806404B1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
DE60142861D1 (de) Verwendung von IL-10 Rezeptor beta antagonistische Antikörper zur Hemmung einer IL-TIF/IL-21 Induktion von Akutphasen-Proteine
CY1112101T1 (el) Νευροτροφικοι παραγοντες
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DK3184545T3 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
DE122010000023I2 (de) IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.
BR0114646A (pt) anticorpos anti-lt-beta-r humanizados
SV2008002972A (es) Composiciones, metodos y usos de anticuerpos humanos anti-il-23 ref. cen5117sv
MX2022000367A (es) Heterodimeros, metodos y uso de los mismos.
ATE408624T1 (de) Verfahren zur reinigung von fsh
ATE348633T1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
EP1503795A4 (en) USE OF STRESS PROTEINS TO IMPROVE THE EFFICIENCY OF THERAPEUTIC ANTIBODIES
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
ATE365319T1 (de) Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
DE69912839D1 (de) Nrihydroxstilbene enthaltende produkte und deren derivate und verfahren zur deren herstellung und ihre verwendung
DE60101851D1 (de) Verfahren zur herstellung von platinmaterial verstärkt mittels fein verteilter oxide.
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
DE69840326D1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
ATE350387T1 (de) Verfahren zur reinigung von molekülen unter verwendung von unverzweigten alkyldiolen mit einständigen hydroxylgruppen
DE602006009901D1 (de) Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
DE602006014140D1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
DE60108105D1 (de) Verfahren zur Herstellung von 5-substituierten Isobenzofuranen